Overview

Auto Injectors Market Introduction

Auto Injectors Market is projected to value over USD 86.3 billion by 2027 end and register a CAGR of over 20.1% during the forecast period 2020 to 2027. 

Auto injector is a medical device that is used for dispensing a single drug dose, life-saving drugs in particular. These auto injectors are generally syringes that are spring-loaded and are peculiarly designed for safe and easy drug administration. The method of injectable drug delivery is a market-driven on technology and it has experienced an exemplar shift in recent years. Currently, the conventionally used devices for self-injection, which were rarely used for insulin and human growth hormone delivery are replaced by advanced auto injectors. 

Auto injectors have experienced a significant adoption owing to the benefits provided over traditional devices like prototype syringes for drug delivery to parents. The risks related to the traditional syringes are a risk of drug discontinuity and missed injection. These risks are eliminated by auto injectors and the overall cost of healthcare is also reduced as the number of hospital visits are curbed down eventually. 

Therefore, auto injectors have assured better patient adherence for treating multiple diseases. Various auto injector alternatives are available which would help the market grow substantially to meet the needs of stimulating innovation, especially in therapeutic areas. The surge of biologics for drug delivery, improvements in the compliance of patients, simplification of self-administration and increasing prevalence of cancer and diabetes are the important factors that stimulate the global auto injectors market growth. Nonetheless, regulatory obstacles, injuries and needle-stick infections impede the market growth.

The global auto injector market is fragmented based on design, technology, product type, application, geography and type. On the basis of the type of product, the market is bifurcated into prefilled and fillable auto injectors. Based on technology, the market is bifurcated into automated and manual auto injectors. On the basis of type, the auto injectors market is segmented into reusable and disposable auto injectors. The auto injector market, based on design is categorized into customized and standardized. There are multiple applications of these devices for treating diseases like anaphylaxis, rheumatoid arthritis, multiple sclerosis and others. Regionally, the report is fragmented into four regions, Europe, North America, Latin America and the Middle East & Africa and the Asia-Pacific.

Key market players included in the global auto injectors market industry are Abbvie, Mylan, ELI Lilly, Ypsomed, Amgen, Becton, Dickinson and Co., Owen Mumford, Consort Medical, Haselmeir, Shl Group, Johnson & Johnson, Teva, Antares Pharma.

Global Auto Injectors Market Segmentation:

By Therapy

• Rheumatoid Arthritis
• Multiple Sclerosis
• Diabetes
• Anaphylaxis
• Other Therapies

By Type

• Disposable Auto Injectors
• Reusable Auto Injectors

By End User

• Home Care Settings
• Hospitals & Clinics

By Region

• North America
• Europe
• Asia Pacific
• Rest of the World

FutureWise Key Takeaways:

•  Growth prospects
•  SWOT analysis 
•  Key trends 
•  Key data-points affecting market growth 

Objectives of the Study:

• To provide with an exhaustive analysis on the global auto injectors market by therapy, by type, by end user and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market 
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific and the rest of the world
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financials and core competencies

Table of Contents

1 Introduction 

    1.1 Objectives of Study 

    1.2 Market Definition 

    1.3 Market Scope 

           1.3.1 Years Considered for the Study

           1.3.2 Markets Covered

    1.4 Currency 

    1.5 Limitations 

    1.6 Stakeholders 

2 Research Methodology 

    2.1 Research Methodology Steps 

    2.2 Secondary and Primary Research Methodology 

           2.2.1 Secondary Research

           2.2.2 Primary Research

                    2.2.2.1 Key Data From Primary Sources

                    2.2.2.2 Key Industry Insights

    2.3 Market Size Estimation Methodology 

    2.4 Market Data Validation and Triangulation 

    2.5 Assumptions for the Study 

3 Executive Summary 

4 Premium Insights 

    4.1 Market Overview 

    4.2 Market, By Type, 2020 vs 2027

    4.3 Geographic Analysis: Market, By Therapy 

    4.4 Market, By End User, 2020 vs 2027 

    4.5 Geographic Snapshot: Market 

5 Market Overview 

    5.1 Introduction 

    5.2 Market Dynamics 

           5.2.1 Drivers

                    5.2.1.1 Growing Prevalence of Targeted Therapies

                    5.2.1.2 Rising Incidence of Anaphylaxis

                    5.2.1.3 Increasing Number of Regulatory Approvals

                    5.2.1.4 Availability of Generic Versions of Autoinjectors

                    5.2.1.5 Favorable Reimbursements and Government Support

                    5.2.1.6 Technological Advancements and Design Development

           5.2.2 Restraints

                    5.2.2.1 Preference for Alternative Drug Delivery Modes

                               5.2.2.1.1 Oral Diabetic Agents and Oral Insulin

                               5.2.2.1.2 Epinephrine Nasal Sprays

           5.2.3 Opportunities

                    5.2.3.1 Patent Expiry of Biologics to Drive the Demand for Biosimilars

           5.2.4 Challenges

                    5.2.4.1 Development of Autoinjectors for Multiple Drug Viscosities

                    5.2.4.2 Lack of Proper Training for Using Autoinjectors

6 Autoinjectors Market, By Therapy

    6.1 Introduction 

    6.2 Rheumatoid Arthritis 

    6.3 Multiple Sclerosis 

    6.4 Diabetes 

    6.5 Anaphylaxis 

    6.6 Other Therapies 

7 Autoinjectors Market, By Type

    7.1 Introduction 

    7.2 Disposable Autoinjectors 

    7.3 Reusable Autoinjectors 

8 Autoinjectors Market, By End User 

    8.1 Introduction 

    8.2 Home Care Settings 

    8.3 Hospitals & Clinics 

9 Autoinjectors Market, By Region 

    9.1 Introduction 

    9.2 North America 

           9.2.1 US

           9.2.2 Canada

    9.3 Europe 

           9.3.1 Germany

           9.3.2 UK

           9.3.3 France

           9.3.4 Rest of Europe

    9.4 Asia Pacific 

           9.4.1 Japan

           9.4.2 China

           9.4.3 India

           9.4.4 RoAPAC

    9.5 Rest of the World 

10 Competitive Landscape 

     10.1 Overview 

     10.2 Market Share Analysis 

     10.3 Market Ranking of OEM Companies 

     10.4 Market Share Analysis, By Therapeutic Area 

             10.4.1 Rheumatoid Arthritis

             10.4.2 Multiple Sclerosis

             10.4.3 Diabetes

             10.4.4 Anaphylaxis

     10.5 Competitive Scenario 

             10.5.1 Product Launches and Approvals

             10.5.2 Expansions

             10.5.3 Agreements, Collaborations, and Partnerships

11 Company Profiles 

     11.1 Abbvie 

     11.2 Mylan 

     11.3 ELI Lilly 

     11.4 Ypsomed 

     11.5 Amgen 

     11.6 Becton, Dickinson and Company 

     11.7 Owen Mumford 

     11.8 Consort Medical 

     11.9 Haselmeier 

     11.10 Shl Group (Scandinavian Health Limited) 

     11.11 Johnson & Johnson (J&J) 

     11.12 Teva 

     11.13 Antares Pharma 

Chapter 12 Research Finding and Conclusion 

Chapter 13  Research Methodology 

Chapter 14  Research Data Source   

Tables

Figures